Gaush Meditech (HKSE:02407) 3-Year EBITDA Growth Rate : 28.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech 3-Year EBITDA Growth Rate?

Gaush Meditech's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 28.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gaush Meditech was 28.00% per year. The lowest was 28.00% per year. And the median was 28.00% per year.

Competitive Comparison of Gaush Meditech's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Gaush Meditech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gaush Meditech's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Gaush Meditech's 3-Year EBITDA Growth Rate falls into.

Gaush Meditech 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Gaush Meditech (HKSE:02407) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Gaush Meditech 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Gaush Meditech's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gaush Meditech (HKSE:02407) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

F7Y:Germany

Address

No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN

Website

https://www.gaush.com

Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Gao Tieta	2201 Interest of corporation controlled by you
Gaush Holding Ltd	2101 Beneficial owner
Cuprite Gem Investments Ltd	2101 Beneficial owner
Warburg Pincus (bermuda) Private Equity Gp Ltd.	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp Llc	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp, L.p.	2201 Interest of corporation controlled by you
Warburg Pincus China-southeast Asia Ii (cayman), L.p.	2201 Interest of corporation controlled by you
Warburg Pincus Partners Ii (cayman), L.p.	2201 Interest of corporation controlled by you

Gaush Meditech (HKSE:02407) Headlines

No Headlines